Education
A provider's guide to 503B outsourcing facilities — FDA registration, cGMP requirements, office stock compounding, and how 503B pharmacies fit into your practice.
A 503B compounding pharmacy — formally called an outsourcing facility — is an FDA-registered facility that compounds sterile and non-sterile medications without requiring individual patient prescriptions. This allows providers to purchase compounded medications for office stock, hospital use, and facility-level dispensing.
Traditional compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. They compound on a patient-by-patient basis with individual prescriptions. A 503B outsourcing facility operates under Section 503B, which grants several distinct capabilities:
503B outsourcing facilities are particularly valuable for:
Because 503B facilities are FDA-registered, they must meet cGMP standards that include:
Many practices benefit from working with both types. A 503A pharmacy like Promise Pharmacy provides custom patient-specific formulations with clinical pharmacist support, while a 503B facility provides standardized office-stock compounds. The right mix depends on your practice model, patient volume, and compound needs.
For a detailed comparison: 503A vs 503B Compounding Pharmacy
FAQ